whatshot

RCUS   $14.71  3.01% Market Closed After Close 14.7 -0.07%

Arcus Biosciences Inc
show_chart Advanced Chart of RCUS
Last Events:

2023-08-05 Trend Power changed from almost flat to slow.

2023-08-04 Trend Power changed from slow to almost flat.

2023-08-03 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-02 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-07-29 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-07-28 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-07-27 Trend pattern changed from расширяющийся канал to канал.

2023-07-27 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

Current temperature: 0.72
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 11
Target Price Mean 34.00
Mean unverified/preliminary 34.00 / 34.00
Target Price Low / High 20.00 / 46.00
Median / STD DEV 36.00 / 9.75
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell None ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy Buy None
ma50 None None None
ma100 ActivelyBuy Buy None
Candlestick PatternNov. 4, 2024 Bullish Three Inside Up - pattern is a made up of three candlesticks. Big black candlestick appears on the first day in a downtrend. The second day body is engulfed by the body of the first day. A white candlestick on the third day with a higher close than the second day. Considered to be a bullish reversal pattern.
ISIN US03969F1093
ceo Dr. Terry J. Rosen Ph.D.
Website https://www.arcusbio.com
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.